The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: Intestinal absorption properties, biochemical and pharmacodynamic effects

Thrombosis Research

Volumn 101, Issue 3, 2001, Pages 171-181

  Gustafsson, David ^a   Nyström, Jan Erik ^a   Carlsson, Stefan ^a   Bredberg, Ulf ^a   Eriksson, Ulf ^a   Gyzander, Erika ^a   Elg, Margareta ^a   Antonsson, Thomas ^a   Hoffmann, Kurt Jürgen ^a   Ungell, Anna Lena ^a   Sörensen, Henrik ^a   Någård, Sofia ^a   Abrahamsson, Anna ^a   Bylund, Ruth ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Intestinal permeability; Man; Oral administration; Rat; Thrombin inhibitor

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PRODRUG; THROMBIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG INHIBITION; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; MALE; PARTITION COEFFICIENT; PERMEABILITY; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOSIS;

EID: 0035251672     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00399-6     Document Type: Article

References (28)

1. Hypoprothrombinaemia produced by methylene-bis-(hydroxycoumarin), its use in thrombosis
2. A preparation from spoiled sweet clover (3, 3′-methylene-bis-(4-hydroxycoumarin)) which prolongs coagulation and prothrombin time of the blood: A clinical study
3. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
4. Biverkningsnytt. Rekordantal rapporter 1992
5. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside
6. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat
7. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis
8. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes
9. Melagatran, an oral active site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
10. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low molecular weight heparin in a caval vein thrombosis model in the rat
11. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in the canine model of coronary artery thrombolysis
12. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT
13. Pharmacokinetics of melagatran, a novel thrombin inhibitor, in healthy volunteers following intravenous, subcutaneous and oral administration
14. Small, noncovalent serine protease inhibitors
15. Argatroban analogs: Synthesis, thrombin inhibitory activity and cell permeability of aminoheterocyclic guanidine surrogates
16. L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
17. Benzylamine-based selective and orally bioavailable inhibitors of thrombin
18. The discovery of orally available thrombin inhibitors; studies towards the optimisation of CGH1668
19. Improvement of the intestinal absorption of a peptidomimetic, boronic acid thrombin inhibitor possibly utilizing the oligopeptide transporter
20. Selective paracellular permeability in two models of intestinal absorption: Cultured monolayers of human intestinal epithelial cells and rat intestinal segments
21. Single and repeated oral dosing of H 376/95, a prodrug to the direct thrombin inhibitor melagatran, to young healthy male subjects
22. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in men
23. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers
24. Methro II: Dose-response study of the novel oral, direct thrombin inhibitor, H 376/95 and its subcutaneous formulation melagatran, compared with dalteparin as thromboembolic prophylaxis after total hip or knee replacement